Novartis: Goldman Sachs no longer Buy

(CercleFinance.com) - Goldman Sachs on Thursday downgraded its recommendation on Novartis shares to 'neutral' from 'buy', citing a limited number of near-term catalysts.


In a research note, the analyst justifies his decision by the stock's strong recent performance, the recent upward revision of consensus forecasts, and a lack of immediate innovation drivers.

At 105 Swiss francs, compared with 119 previously, his new price target only highlights a potential upside of around 2%.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.